生物活性：Ditiocarb-d10 (Diethyldithiocarbamic acid-d10) is the deuterium labeled Ditiocarb (HY-126363)[1]. Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunoresearch of high risk breast cancer[2][3][4].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Ditiocarb-d10 相关抗体:
CD4 Antibody
TARBP2 Antibody (YA1433)
SAMHD1 Antibody (YA1542)
SV40 T Antigen Antibody (YA3256)
CLEC12A Antibody (YA1419)
Tat SF1 Antibody (YA2886)
分子量：159.34
Formula：C5HD10NS2
CAS 号：1261734-83-1
非标记 CAS：147-84-2
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (543 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293.
[3]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44.
 [Content Brief]
[4]. Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6(1):9-12.
 [Content Brief]